Lenacapavir PrEP ‘special cases’: young people, missed doses and drug interactions

An entire session at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda was devoted to the PURPOSE 1 and PURPOSE 2 studies of the six-monthly injectable PrEP drug lenacapavir, which reflects its importance as a step forward in HIV prevention. Lenacapavir for PrEP has recently received positive decisions by drug regulators in the US and Europe . During the conference, the World Health Organization issued guidelines recommending it .